<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01254539</url>
  </required_header>
  <id_info>
    <org_study_id>Extension CMN/ELA</org_study_id>
    <secondary_id>2006-003096-12</secondary_id>
    <secondary_id>EC07/90762</secondary_id>
    <nct_id>NCT01254539</nct_id>
  </id_info>
  <brief_title>Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA)</brief_title>
  <official_title>Phase I/II Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Morales Meseguer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación Diógenes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to assess the feasibility and the security of the
      intraspinal and intrathecal infusion of autologous bone marrow stem cells for the treatment
      of Amyotrophic Lateral Sclerosis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Amyotrophic Lateral Sclerosis (ALS) typically endure a progressive paralysis
      due to the continued loss of motoneurons that leads them to death in less than 5 years. No
      treatment has changed its natural history. Intraspinal injections of bone marrow mononuclear
      cells (MNC) have been able to ameliorate the course of ALS in murine models, acting as pumps
      of trophic factors that keep the motoneurons functional. Moreover, the clinical trial (Study
      NCT00855400 on www.ClinicalTrials.gov) conducted by our research group to determine the
      safety and efficacy of Autologous Stem Cell transplantation in Amyotrophic Lateral Sclerosis
      in humans, found that this procedure is feasible and safe. Continuing with that study, we
      have designed a phase I/II clinical trial to check the feasibility of the intraspinal and
      intrathecal infusion of autologous bone marrow stem cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>Every 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological variables: The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALS-FRS), Medical Research Council (MRC) and Norris scales</measure>
    <time_frame>Every 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of adverse events</measure>
    <time_frame>Every week / month depending on the study phase</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurophysiological variables: Electromyography, polysomnography, evoked potentials</measure>
    <time_frame>Every 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroradiological variables: Spinal Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Every 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory variables: Maximal inspiratory pressure (PIM), Maximal expiratory pressure (PEM), sniff nasal, oxymetry.</measure>
    <time_frame>Every 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological variables: Health Questionnaire (EuroQol-5D), The Profile of Mood States (POMS)</measure>
    <time_frame>Every 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Autologous bone marrow stem cells intraspinal transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal infusion of autologous bone marrow stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal infusion of placebo (saline solution).</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients were infused  2 ml of saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laminectomy and bone marrow stem cells transplantation</intervention_name>
    <description>Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.
T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation</description>
    <arm_group_label>Autologous bone marrow stem cells intraspinal transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrathecal infusion of autologous bone marrow stem cells</intervention_name>
    <description>Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.
Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.</description>
    <arm_group_label>Intrathecal infusion of autologous bone marrow stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrathecal infusion of placebo (saline solution).</intervention_name>
    <description>Patients were infused  2 ml of saline solution</description>
    <arm_group_label>Intrathecal infusion of placebo (saline solution).</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnose established following the World Federation of Neurology criteria

          -  More than 6 and less than 36 months of evolution of the disease

          -  Medullar onset of the disease

          -  More than 18 and less than 70 years old

          -  Forced Vital Capacity ≥ 50%

          -  Total time of oxygen saturation &lt;90% inferior to 5% of the sleeping time

          -  Signed informed consent

        Exclusion Criteria:

          -  Neurological or psychiatric concomitant disease

          -  Need of parenteral or enteral nutrition through percutaneous endoscopic gastrostomy
             or nasogastric tube

          -  Concomitant systemic disease

          -  Treatment with corticosteroids, immunoglobulins or immunosuppressors during the last
             12 months

          -  Inclusion in other clinical trials

          -  Unability to understand the informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose María Moraleda Jiménez, M.D. PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paqui Iniesta Martínez</last_name>
    <email>iniesmar@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paqui Iniesta Martínez</last_name>
    </contact>
    <investigator>
      <last_name>Jose María Moraleda Jiménez, M.D. PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://red-tercel.com/</url>
    <description>Spanish Cell Therapy Network</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/mesh/68000690</url>
    <description>Amyotrophic Lateral Sclerosis</description>
  </link>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>December 7, 2010</lastchanged_date>
  <firstreceived_date>December 3, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Javier Júdez Gutiérrez</name_title>
    <organization>Fundación para la Formación e Investigación Sanitarias de la Región de Murcia</organization>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Autologous</keyword>
  <keyword>Safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
</clinical_study>
